Abstract
Monocytes are key players in atherosclerotic. Human monocytes display a considerable heterogeneity and at least three subsets can be distinguished. While the role of monocyte subset heterogeneity has already been well investigated in coronary artery disease (CAD), the knowledge about monocytes and their heterogeneity in peripheral artery occlusive disease (PAOD) still is limited. Therefore, we aimed to investigate monocyte subset heterogeneity in patients with PAOD. Peripheral blood was obtained from 143 patients suffering from PAOD (Rutherford stage I to VI) and three monocyte subsets were identified by flow cytometry: CD14++CD16− classical monocytes, CD14+CD16++ non-classical monocytes and CD14++CD16+ intermediate monocytes. Additionally the expression of distinct surface markers (CD106, CD162 and myeloperoxidase MPO) was analyzed. Proportions of CD14++CD16+ intermediate monocyte levels were significantly increased in advanced stages of PAOD, while classical and non-classical monocytes displayed no such trend. Moreover, CD162 and MPO expression increased significantly in intermediate monocyte subsets in advanced disease stages. Likewise, increased CD162 and MPO expression was noted in CD14++CD16− classical monocytes. These data suggest substantial dynamics in monocyte subset distributions and phenotypes in different stages of PAOD, which can either serve as biomarkers or as potential therapeutic targets to decrease the inflammatory burden in advanced stages of atherosclerosis.
Highlights
A higher Rutherford scale associated with increased rates of myocardial infarction, stroke, and death, providing evidence that peripheral artery occlusive disease (PAOD) serves as marker of disease severity and predictor for other cardiovascular events beyond its typical peripheral clinical manifestations[12]
The results showed that subset distributions with respect to the “intermediate” CD14++CD16+ monocytes as well as the “classical” CD14++CD16− monocytes were similar between patients suffering from PAOD only, compared to patients suffering from PAOD and from coronary and/or carotid artery disease
Despite advances in treatment strategies, current clinical outcomes remain poor in patients with PAOD
Summary
Likewise, increased CD162 and MPO expression was noted in CD14++CD16− classical monocytes These data suggest substantial dynamics in monocyte subset distributions and phenotypes in different stages of PAOD, which can either serve as biomarkers or as potential therapeutic targets to decrease the inflammatory burden in advanced stages of atherosclerosis. A higher Rutherford scale associated with increased rates of myocardial infarction, stroke, and death, providing evidence that PAOD serves as marker of disease severity and predictor for other cardiovascular events beyond its typical peripheral clinical manifestations[12]. This disease causes limitations in mobility and impaired quality of life, but contributes to increased health care expenditures
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
